

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use TEFLARO safely and effectively. See full prescribing information for TEFLARO.

**TEFLARO® (ceftaroline fosamil) injection for intravenous (IV) use**

**Initial U.S. Approval: 2010**

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.

**RECENT MAJOR CHANGES**

Dosage and Administration (2.3) 10/2012  
Dosage and Administration (2.3) XX/XXXX

**INDICATIONS AND USAGE**

Teflaro® is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria:

- Acute bacterial skin and skin structure infections (ABSSSI) (1.1)
- Community-acquired bacterial pneumonia (CABP) (1.2)

**DOSAGE AND ADMINISTRATION**

- 600 mg every 12 hours by IV infusion administered over 1 hour in adults ≥ 18 years of age (2.1)
- Dosage adjustment in patients with renal impairment (2.2)

Estimated Creatinine Clearance# (mL/min)	Teflaro Dosage Regimen
> 50	No dosage adjustment necessary
> 30 to ≤ 50	400 mg IV (over 1 hour) every 12 hours
≥ 15 to ≤ 30	300 mg IV (over 1 hour) every 12 hours
End-stage renal disease (ESRD), including hemodialysis	200 mg IV (over 1 hour) every 12 hours

# As calculated using the Cockcroft-Gault formula

**DOSAGE FORMS AND STRENGTHS**

600 mg or 400 mg of sterile Teflaro powder in single-use 20 mL vials. (3)

**CONTRAINDICATIONS**

- Known serious hypersensitivity to ceftaroline or other members of the cephalosporin class. (4)

**WARNINGS AND PRECAUTIONS**

- Serious hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibiotics, including ceftaroline. Exercise caution in patients with known hypersensitivity to beta-lactam antibiotics. (5.1)
- Clostridium difficile*-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including Teflaro. Evaluate if diarrhea occurs. (5.2)
- Direct Coombs' test seroconversion has been reported with Teflaro. If anemia develops during or after therapy, a diagnostic workup for drug-induced hemolytic anemia should be performed and consideration given to discontinuation of Teflaro. (5.3)

**ADVERSE REACTIONS**

The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash. (6.3)

To report SUSPECTED ADVERSE REACTIONS, contact Forest Pharmaceuticals, Inc., at 1-800-678-1605 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**USE IN SPECIFIC POPULATIONS**

- Dosage adjustment is required in patients with moderate or severe renal impairment and in ESRD patients, including patients on hemodialysis. (2.2, 12.3)

See 17 for PATIENT COUNSELING INFORMATION

Revised: Month/Year

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**1 INDICATIONS AND USAGE**

- 1.1 Acute Bacterial Skin and Skin Structure Infections
- 1.2 Community-Acquired Bacterial Pneumonia
- 1.3 Usage

**2 DOSAGE AND ADMINISTRATION**

- 2.1 Recommended Dosage
- 2.2 Patients with Renal Impairment
- 2.3 Preparation of Solutions
  - 2.3.1 Preparation of 600 mg of Teflaro dose in 50 mL
  - 2.3.2 Preparation of 400 mg of Teflaro dose in 50 mL

**3 DOSAGE FORMS AND STRENGTHS**

**4 CONTRAINDICATIONS**

**5 WARNINGS AND PRECAUTIONS**

- 5.1 Hypersensitivity Reactions
- 5.2 *Clostridium difficile*-associated Diarrhea
- 5.3 Direct Coombs' Test Seroconversion
- 5.4 Development of Drug-Resistant Bacteria

**6 ADVERSE REACTIONS**

- 6.1 Adverse Reactions from Clinical Trials
- 6.2 Serious Adverse Events and Adverse Events Leading to Discontinuation
- 6.3 Most Common Adverse Reactions

- 6.4 Other Adverse Reactions Observed During Clinical Trials of Teflaro

**7 DRUG INTERACTIONS**

**8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Patients with Renal Impairment

**10 OVERDOSAGE**

**11 DESCRIPTION**

**12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics
- 12.4 Microbiology

**13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**14 CLINICAL TRIALS**

- 14.1 Acute Bacterial Skin and Skin Structure Infections
- 14.2 Community-Acquired Bacterial Pneumonia

**15 REFERENCES**

**16 HOW SUPPLIED/STORAGE AND HANDLING**  
**17 PATIENT COUNSELING INFORMATION**

\*Sections or subsections omitted from the full prescribing information are not listed.

---

## 1 FULL PRESCRIBING INFORMATION

### 3 1. INDICATIONS AND USAGE

5 Teflaro® (ceftaroline fosamil) is indicated for the treatment of patients with the following infections caused  
6 by susceptible isolates of the designated microorganisms.

#### 8 1.1 Acute Bacterial Skin and Skin Structure Infections

10 Teflaro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused  
11 by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: *Staphylococcus*  
12 *aureus* (including methicillin-susceptible and -resistant isolates), *Streptococcus pyogenes*, *Streptococcus*  
13 *agalactiae*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Klebsiella oxytoca*.

#### 15 1.2 Community-Acquired Bacterial Pneumonia

17 Teflaro is indicated for the treatment of community-acquired bacterial pneumonia (CABP) caused by  
18 susceptible isolates of the following Gram-positive and Gram-negative microorganisms: *Streptococcus*  
19 *pneumoniae* (including cases with concurrent bacteremia), *Staphylococcus aureus* (methicillin-susceptible  
20 isolates only), *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, and *Escherichia coli*.

#### 22 1.3 Usage

24 To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other  
25 antibacterial drugs, Teflaro should be used to treat only ABSSSI or CABP that are proven or strongly  
26 suspected to be caused by susceptible bacteria. Appropriate specimens for microbiological examination  
27 should be obtained in order to isolate and identify the causative pathogens and to determine their  
28 susceptibility to ceftaroline. When culture and susceptibility information are available, they should be  
29 considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology  
30 and susceptibility patterns may contribute to the empiric selection of therapy.

## 33 2. DOSAGE AND ADMINISTRATION

### 35 2.1 Recommended Dosage

37 The recommended dosage of Teflaro is 600 mg administered every 12 hours by intravenous (IV) infusion  
38 over 1 hour in patients  $\geq 18$  years of age. The duration of therapy should be guided by the severity and site  
39 of infection and the patient's clinical and bacteriological progress.

40 The recommended dosage and administration by infection is described in Table 1.

49  
50

**Table 1: Dosage of Teflaro by Infection**

Infection	Dosage	Frequency	Infusion Time (hours)	Recommended Duration of Total Antimicrobial Treatment
Acute Bacterial Skin and Skin Structure Infection (ABSSSI)	600 mg	Every 12 hours	1	5-14 days
Community-Acquired Bacterial Pneumonia (CABP)	600 mg	Every 12 hours	1	5-7 days

51  
52  
53  
54

## 2.2 Patients with Renal Impairment

**Table 2: Dosage of Teflaro in Patients with Renal Impairment**

Estimated CrCl <sup>a</sup> (mL/min)	Recommended Dosage Regimen for Teflaro
> 50	No dosage adjustment necessary
> 30 to ≤ 50	400 mg IV (over 1 hour) every 12 hours
≥ 15 to ≤ 30	300 mg IV (over 1 hour) every 12 hours
End-stage renal disease, including hemodialysis <sup>b</sup>	200 mg IV (over 1 hour) every 12 hours <sup>c</sup>

<sup>a</sup> Creatinine clearance (CrCl) estimated using the Cockcroft-Gault formula.

<sup>b</sup> End-stage renal disease is defined as CrCl < 15 mL/min.

<sup>c</sup> Teflaro is hemodialyzable; thus Teflaro should be administered after hemodialysis on hemodialysis days.

55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66

## 2.3 Preparation of Solutions

Aseptic technique must be followed in preparing the infusion solution. The contents of Teflaro vial should be constituted with 20 mL Sterile Water for Injection, USP; or 0.9% of sodium chloride injection (normal saline); or 5% of dextrose injection; or lactated ringer's injection. The preparation of Teflaro solutions is summarized in Table 3.

**Table 3: Preparation of Teflaro for Intravenous Use**

Dosage Strength (mg)	Volume of Diluent To Be Added (mL)	Approximate Ceftaroline fosamil Concentration (mg/mL)	Amount to Be Withdrawn
400	20	20	Total Volume
600	20	30	Total Volume

67  
68  
69  
70  
71

The constituted solution must be further diluted in range between 50 mL to 250 mL before infusion into patients. Use the same diluent for this further dilution, unless sterile water for injection was used earlier. If sterile water for injection was used earlier, then appropriate infusion solutions include: 0.9% Sodium Chloride Injection, USP (normal saline); 5% Dextrose Injection, USP; 2.5% Dextrose Injection, USP, and

72 0.45% Sodium Chloride Injection, USP; or Lactated Ringer's Injection, USP. The resulting solution should  
73 be administered over approximately 1 hour.

74  
75 Constitution time is less than 2 minutes. Mix gently to constitute and check to see that the contents have  
76 dissolved completely. Parenteral drug products should be inspected visually for particulate matter prior to  
77 administration.

78  
79 The color of Teflaro infusion solutions ranges from clear, light to dark yellow depending on the  
80 concentration and storage conditions. When stored as recommended, the product potency is not affected.

81  
82 **Stability in Baxter® Mini-Bag Plus™**: Solutions of Teflaro in concentrations ranging from 4 to 12 mg/mL  
83 in Baxter Mini-Bag Plus containers with 0.9% Sodium Chloride Injection may be stored for up to 6 hours at  
84 room temperature or for up to 24 hours at 2°C to 8°C (36°F to 46°F). Stability testing in the Baxter Mini-  
85 Bag Plus has solely been conducted on 50 mL and 100 mL containers (0.9% Sodium Chloride Injection).

86  
87 **Stability in Infusion Bag**: Studies have shown that the constituted solution in the infusion bag should be  
88 used within 6 hours when stored at room temperature or within 24 hours when stored under refrigeration at  
89 2 to 8° C (36 to 46° F).

90  
91 The compatibility of Teflaro with other drugs has not been established. Teflaro should not be mixed with or  
92 physically added to solutions containing other drugs.

93  
94 **Only for the 50 mL infusion bags dilution, see the instructions listed in 2.3.1 and 2.3.2.**

95  
96 **2.3.1 Preparation of 600 mg of Teflaro dose in 50 mL**

97  
98 Withdraw 20 mL of diluent from the infusion bag. Proceed to inject entire content of the Teflaro vial into  
99 the bag to provide a total volume of 50 mL. The resultant concentration is approximately 12 mg/mL.

100  
101 **2.3.2 Preparation of 400 mg of Teflaro dose in 50 mL**

102  
103 Withdraw 20 mL of diluent from the infusion bag. Proceed to inject entire content of the Teflaro vial into  
104 the bag to provide a total volume of 50 mL. The resultant concentration is approximately 8 mg/mL.

105  
106

### 107 **3. DOSAGE FORMS AND STRENGTHS**

108  
109 Teflaro is supplied in single-use, clear glass vials containing either 600 mg or 400 mg of sterile ceftaroline  
110 fosamil powder.

### 111 **4. CONTRAINDICATIONS**

112  
113  
114  
115 Teflaro is contraindicated in patients with known serious hypersensitivity to ceftaroline or other members of  
116 the cephalosporin class. Anaphylaxis and anaphylactoid reactions have been reported with ceftaroline.

117  
118

119

120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167

## 5. WARNINGS AND PRECAUTIONS

### 5.1 Hypersensitivity Reactions

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterials. Before therapy with Teflaro is instituted, careful inquiry about previous hypersensitivity reactions to other cephalosporins, penicillins, or carbapenems should be made. If this product is to be given to a penicillin- or other beta-lactam-allergic patient, caution should be exercised because cross sensitivity among beta-lactam antibacterial agents has been clearly established.

If an allergic reaction to Teflaro occurs, the drug should be discontinued. Serious acute hypersensitivity (anaphylactic) reactions require emergency treatment with epinephrine and other emergency measures, that may include airway management, oxygen, intravenous fluids, antihistamines, corticosteroids, and vasopressors as clinically indicated.

### 5.2 *Clostridium difficile*-associated Diarrhea

*Clostridium difficile*-associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of *C. difficile*.

*C. difficile* produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, antibacterials not directed against *C. difficile* should be discontinued, if possible. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated [see Adverse Reactions (6.3)].

### 5.3 Direct Coombs' Test Seroconversion

Seroconversion from a negative to a positive direct Coombs' test result occurred in 120/1114 (10.8%) of patients receiving Teflaro and 49/1116 (4.4%) of patients receiving comparator drugs in the four pooled Phase 3 trials.

In the pooled Phase 3 CABP trials, 51/520 (9.8%) of Teflaro-treated patients compared to 24/534 (4.5%) of ceftriaxone-treated patients seroconverted from a negative to a positive direct Coombs' test result. No adverse reactions representing hemolytic anemia were reported in any treatment group.

If anemia develops during or after treatment with Teflaro, drug-induced hemolytic anemia should be considered. Diagnostic studies including a direct Coombs' test, should be performed. If drug-induced hemolytic anemia is suspected, discontinuation of Teflaro should be considered and supportive care should be administered to the patient (i.e. transfusion) if clinically indicated.

168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215

## 5.4 Development of Drug-Resistant Bacteria

Prescribing Teflaro in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

## 6. ADVERSE REACTIONS

The following serious events are described in greater detail in the Warnings and Precautions section

- Hypersensitivity reactions [see Warnings and Precautions (5.1)]
- *Clostridium difficile*-associated diarrhea [see Warnings and Precautions (5.2)]
- Direct Coombs' test seroconversion [see Warnings and Precautions (5.3)]

### 6.1 Adverse Reactions from Clinical Trials

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be compared directly to rates from clinical trials of another drug and may not reflect rates observed in practice.

Teflaro was evaluated in four controlled comparative Phase 3 clinical trials (two in ABSSSI and two in CABP) which included 1300 adult patients treated with Teflaro (600 mg administered by IV over 1 hour every 12h) and 1297 patients treated with comparator (vancomycin plus aztreonam or ceftriaxone) for a treatment period up to 21 days. The median age of patients treated with Teflaro was 54 years, ranging between 18 and 99 years old. Patients treated with Teflaro were predominantly male (63%) and Caucasian (82%).

### 6.2 Serious Adverse Events and Adverse Events Leading to Discontinuation

In the four pooled Phase 3 clinical trials, serious adverse events occurred in 98/1300 (7.5%) of patients receiving Teflaro and 100/1297 (7.7%) of patients receiving comparator drugs. The most common SAEs in both the Teflaro and comparator treatment groups were in the respiratory and infection system organ classes (SOC). Treatment discontinuation due to adverse events occurred in 35/1300 (2.7%) of patients receiving Teflaro and 48/1297 (3.7%) of patients receiving comparator drugs with the most common adverse events leading to discontinuation being hypersensitivity for both treatment groups at a rate of 0.3% in the Teflaro group and 0.5% in comparator group.

### 6.3 Most Common Adverse Reactions

No adverse reactions occurred in greater than 5% of patients receiving Teflaro. The most common adverse reactions occurring in > 2% of patients receiving Teflaro in the pooled phase 3 clinical trials were diarrhea, nausea, and rash.

Table 4 lists adverse reactions occurring in  $\geq 2\%$  of patients receiving Teflaro in the pooled Phase 3 clinical trials.

216  
217  
218

**Table 4: Adverse Reactions Occurring in  $\geq 2\%$  of Patients Receiving Teflaro in the Pooled Phase 3 Clinical Trials**

System Organ Class/ Preferred Term	Pooled Phase 3 Clinical Trials (four trials, two in ABSSSI and two in CABP)	
	Teflaro (N=1300)	Pooled Comparators <sup>a</sup> (N=1297)
<b>Gastrointestinal disorders</b>		
Diarrhea	5 %	3 %
Nausea	4 %	4 %
Constipation	2 %	2 %
Vomiting	2 %	2 %
<b>Investigations</b>		
Increased transaminases	2%	3 %
<b>Metabolism and nutrition disorders</b>		
Hypokalemia	2 %	3 %
<b>Skin and subcutaneous tissue disorders</b>		
Rash	3%	2%
<b>Vascular disorders</b>		
Phlebitis	2%	1%

<sup>a</sup> Comparators included vancomycin 1 gram IV every 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI trials, and ceftriaxone 1 gram IV every 24h in the Phase 3 CABP trials.

219  
220  
221

#### 6.4 Other Adverse Reactions Observed During Clinical Trials of Teflaro

222

Following is a list of additional adverse reactions reported by the 1740 patients who received Teflaro in any clinical trial with incidences less than 2%. Events are categorized by System Organ Class.

225

**Blood and lymphatic system disorders** - Anemia, Eosinophilia, Neutropenia, Thrombocytopenia

226

**Cardiac disorders** - Bradycardia, Palpitations

227

**Gastrointestinal disorders** - Abdominal pain

228

**General disorders and administration site conditions** - Pyrexia

229

**Hepatobiliary disorders** - Hepatitis

230

**Immune system disorders** - Hypersensitivity, Anaphylaxis

231

**Infections and infestations** - *Clostridium difficile* colitis

232

**Metabolism and nutrition disorders** - Hyperglycemia, Hyperkalemia

233

**Nervous system disorders** - Dizziness, Convulsion

234

**Renal and urinary disorders** - Renal failure

235

**Skin and subcutaneous tissue disorders** - Urticaria

236

237

249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296

## 7. DRUG INTERACTIONS

No clinical drug-drug interaction studies have been conducted with Teflaro. There is minimal potential for drug-drug interactions between Teflaro and CYP450 substrates, inhibitors, or inducers; drugs known to undergo active renal secretion; and drugs that may alter renal blood flow [see *Clinical Pharmacology (12.3)*].

## 8. USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### Category B.

Developmental toxicity studies performed with ceftaroline fosamil in rats at IV doses up to 300 mg/kg demonstrated no maternal toxicity and no effects on the fetus. A separate toxicokinetic study showed that ceftaroline exposure in rats (based on AUC) at this dose level was approximately 8 times the exposure in humans given 600 mg every 12 hours. There were no drug-induced malformations in the offspring of rabbits given IV doses of 25, 50, and 100 mg/kg, despite maternal toxicity. Signs of maternal toxicity appeared secondary to the sensitivity of the rabbit gastrointestinal system to broad-spectrum antibacterials and included changes in fecal output in all groups and dose-related reductions in body weight gain and food consumption at  $\geq 50$  mg/kg; these were associated with an increase in spontaneous abortion at 50 and 100 mg/kg. The highest dose was also associated with maternal moribundity and mortality. An increased incidence of a common rabbit skeletal variation, angulated hyoid alae, was also observed at the maternally toxic doses of 50 and 100 mg/kg. A separate toxicokinetic study showed that ceftaroline exposure in rabbits (based on AUC) was approximately 0.8 times the exposure in humans given 600 mg every 12 hours at 25 mg/kg and 1.5 times the human exposure at 50 mg/kg.

Ceftaroline fosamil did not affect the postnatal development or reproductive performance of the offspring of rats given IV doses up to 450 mg/kg/day. Results from a toxicokinetic study conducted in pregnant rats with doses up to 300 mg/kg suggest that exposure was  $\geq 8$  times the exposure in humans given 600 mg every 12 hours.

There are no adequate and well-controlled trials in pregnant women. Teflaro should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### 8.3 Nursing Mothers

It is not known whether ceftaroline is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Teflaro is administered to a nursing woman.

### 8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344

## 8.5 Geriatric Use

Of the 1300 patients treated with Teflaro in the Phase 3 ABSSSI and CABP trials, 397 (30.5%) were  $\geq 65$  years of age. The clinical cure rates in the Teflaro group (Clinically Evaluable [CE] Population) were similar in patients  $\geq 65$  years of age compared with patients  $< 65$  years of age in both the ABSSSI and CABP trials.

The adverse event profiles in patients  $\geq 65$  years of age and in patients  $< 65$  years of age were similar. The percentage of patients in the Teflaro group who had at least one adverse event was 52.4% in patients  $\geq 65$  years of age and 42.8% in patients  $< 65$  years of age for the two indications combined.

Ceftaroline is excreted primarily by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in this age group and it may be useful to monitor renal function. Elderly subjects had greater ceftaroline exposure relative to non-elderly subjects when administered the same single dose of Teflaro. However, higher exposure in elderly subjects was mainly attributed to age-related changes in renal function. Dosage adjustment for elderly patients should be based on renal function [see *Dosage and Administration (2.2) and Clinical Pharmacology (12.3)*].

## 8.6 Patients with Renal Impairment

Dosage adjustment is required in patients with moderate ( $\text{CrCl} > 30$  to  $\leq 50$  mL/min) or severe ( $\text{CrCl} \geq 15$  to  $\leq 30$  mL/min) renal impairment and in patients with end-stage renal disease (ESRD – defined as  $\text{CrCl} < 15$  mL/min), including patients on hemodialysis (HD) [see *Dosage and Administration (2.2) and Clinical Pharmacology (12.3)*].

## 10. OVERDOSAGE


In the event of overdose, Teflaro should be discontinued and general supportive treatment given. Ceftaroline can be removed by hemodialysis. In subjects with ESRD administered 400 mg of Teflaro, the mean total recovery of ceftaroline in the dialysate following a 4-hour hemodialysis session started 4 hours after dosing was 76.5 mg (21.6% of the dose). However, no information is available on the use of hemodialysis to treat overdosage [see *Clinical Pharmacology (12.3)*].

## 11. DESCRIPTION

Teflaro is a sterile, semi-synthetic, broad-spectrum, prodrug antibacterial of cephalosporin class of beta-lactams ( $\beta$ -lactams). Chemically, the prodrug, ceftaroline fosamil monoacetate monohydrate is (6*R*,7*R*)-7-[(2*Z*)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetamido]-3-[[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate monoacetate monohydrate. Its molecular weight is 762.75. The empirical formula is  $\text{C}_{22}\text{H}_{21}\text{N}_8\text{O}_8\text{PS}_4 \cdot \text{C}_2\text{H}_4\text{O}_2 \cdot \text{H}_2\text{O}$ .

345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357

**Figure 1: Chemical structure of ceftaroline fosamil**



358 Teflaro vials contain either 600 mg or 400 mg of anhydrous ceftaroline fosamil. The powder for injection is  
359 formulated from ceftaroline fosamil monoacetate monohydrate, a pale yellowish-white to light yellow  
360 sterile powder. All references to ceftaroline activity are expressed in terms of the prodrug, ceftaroline  
361 fosamil. The powder is constituted for IV injection [see *Dosage and Administration (2.3)*].  
362  
363 Each vial of Teflaro contains ceftaroline fosamil and L-arginine, which results in a constituted solution at  
364 pH 4.8 to 6.5.  
365  
366

## 367 12. CLINICAL PHARMACOLOGY

368  
369 Ceftaroline fosamil is the water-soluble prodrug of the bioactive ceftaroline [see *Clinical Pharmacology*  
370 (12.3)].  
371

### 372 12.1 Mechanism of Action

373  
374 Ceftaroline is an antibacterial drug [see *Clinical Pharmacology (12.4)*].  
375

### 376 12.2 Pharmacodynamics

377  
378 As with other beta-lactam antimicrobial agents, the time that unbound plasma concentration of ceftaroline  
379 exceeds the minimum inhibitory concentration (MIC) of the infecting organism has been shown to best  
380 correlate with efficacy in a neutropenic murine thigh infection model with *S. aureus* and *S. pneumoniae*.  
381

382 Exposure-response analysis of Phase 2/3 ABSSSI trials supports the recommended dosage regimen of  
383 Teflaro 600 mg every 12 hours by IV infusion over 1 hour. For Phase 3 CABP trials, an exposure-response  
384 relationship could not be identified due to the limited range of ceftaroline exposures in the majority of  
385 patients.  
386

### 387 Cardiac Electrophysiology

388  
389 In a randomized, positive- and placebo-controlled crossover thorough QTc study, 54 healthy subjects were  
390 each administered a single dose of Teflaro 1500 mg, placebo, and a positive control by IV infusion over 1  
391 hour. At the 1500 mg dose of Teflaro, no significant effect on QTc interval was detected at peak plasma  
392 concentration or at any other time.

393  
394  
395  
396  
397  
398  
399  
400  
401  
402

### 12.3 Pharmacokinetics

The mean pharmacokinetic parameters of ceftaroline in healthy adults (n=6) with normal renal function after single and multiple 1-hour IV infusions of 600 mg ceftaroline fosamil administered every 12 hours are summarized in Table 5. Pharmacokinetic parameters were similar for single and multiple dose administration.

**Table 5: Mean (Standard Deviation) Pharmacokinetic Parameters of Ceftaroline IV in Healthy Adults**

Parameter	Single 600 mg Dose Administered as a 1-Hour Infusion(n=6)	Multiple 600 mg Doses Administered Every 12 Hours as 1-Hour Infusions for 14 Days(n=6)
<b>C<sub>max</sub> (mcg/mL)</b>	<b>19.0 (0.71)</b>	<b>21.3 (4.10)</b>
<b>T<sub>max</sub> (h)<sup>a</sup></b>	<b>1.00 (0.92-1.25)</b>	<b>0.92 (0.92-1.08)</b>
<b>AUC (mcg•h/mL)<sup>b</sup></b>	<b>56.8 (9.31)</b>	<b>56.3 (8.90)</b>
<b>T<sub>1/2</sub> (h)</b>	<b>1.60 (0.38)</b>	<b>2.66 (0.40)</b>
<b>CL (L/h)</b>	<b>9.58 (1.85)</b>	<b>9.60 (1.40)</b>

<sup>a</sup> Reported as median (range)  
<sup>b</sup> AUC<sub>0-∞</sub>, for single-dose administration; AUC<sub>0-tau</sub>, for multiple-dose administration; C<sub>max</sub>, maximum observed concentration; T<sub>max</sub>, time of C<sub>max</sub>; AUC<sub>0-∞</sub>, area under concentration-time curve from time 0 to infinity; AUC<sub>0-tau</sub>, area under concentration-time curve over dosing interval (0-12 hours); T<sub>1/2</sub>, terminal elimination half-life; CL, plasma clearance

403  
404  
405  
406  
407

The C<sub>max</sub> and AUC of ceftaroline increase approximately in proportion to dose within the single dose range of 50 to 1000 mg. No appreciable accumulation of ceftaroline is observed following multiple IV infusions of 600 mg administered every 12 hours for up to 14 days in healthy adults with normal renal function.

### Distribution

408  
409  
410  
411  
412  
413  
414

The average binding of ceftaroline to human plasma proteins is approximately 20% and decreases slightly with increasing concentrations over 1-50 mcg/mL (14.5-28.0%). The median (range) steady-state volume of distribution of ceftaroline in healthy adult males (n=6) following a single 600 mg IV dose of radiolabeled ceftaroline fosamil was 20.3 L (18.3-21.6 L), similar to extracellular fluid volume.

### Metabolism

415  
416  
417  
418  
419  
420  
421  
422

Ceftaroline fosamil is converted into bioactive ceftaroline in plasma by a phosphatase enzyme and concentrations of the prodrug are measurable in plasma primarily during IV infusion. Hydrolysis of the beta-lactam ring of ceftaroline occurs to form the microbiologically inactive, open-ring metabolite ceftaroline M-1. The mean (SD) plasma ceftaroline M-1 to ceftaroline AUC<sub>0-∞</sub> ratio following a single 600 mg IV infusion of ceftaroline fosamil in healthy adults (n=6) with normal renal function is 28% (3.1%).

423  
424  
425

When incubated with pooled human liver microsomes, ceftaroline was metabolically stable (< 12% metabolic turnover), indicating that ceftaroline is not a substrate for hepatic CYP450 enzymes.

### Excretion

426  
427  
428  
429

Ceftaroline and its metabolites are primarily eliminated by the kidneys. Following administration of a single 600 mg IV dose of radiolabeled ceftaroline fosamil to healthy male adults (n=6), approximately 88% of

430 radioactivity was recovered in urine and 6% in feces within 48 hours. Of the radioactivity recovered in urine  
431 approximately 64% was excreted as ceftaroline and approximately 2% as ceftaroline M-1. The mean (SD)  
432 renal clearance of ceftaroline was 5.56 (0.20) L/h, suggesting that ceftaroline is predominantly eliminated  
433 by glomerular filtration.

434

## 435 **Specific Populations**

436

### 437 **Renal Impairment**

438

439 Following administration of a single 600 mg IV dose of Teflaro, the geometric mean  $AUC_{0-\infty}$  of ceftaroline  
440 in subjects with mild ( $CrCl > 50$  to  $\leq 80$  mL/min,  $n=6$ ) or moderate ( $CrCl > 30$  to  $\leq 50$  mL/min,  $n=6$ ) renal  
441 impairment was 19% and 52% higher, respectively, compared to healthy subjects with normal renal function  
442 ( $CrCl > 80$  mL/min,  $n=6$ ). Following administration of a single 400 mg IV dose of Teflaro, the geometric  
443 mean  $AUC_{0-\infty}$  of ceftaroline in subjects with severe ( $CrCl \geq 15$  to  $\leq 30$  mL/min,  $n=6$ ) renal impairment was  
444 115% higher compared to healthy subjects with normal renal function ( $CrCl > 80$  mL/min,  $n=6$ ). Dosage  
445 adjustment is recommended in patients with moderate and severe renal impairment [*see Dosage and*  
446 *Administration (2.2)*].

447

448 A single 400 mg dose of Teflaro was administered to subjects with ESRD ( $n=6$ ) either 4 hours prior to or 1  
449 hour after hemodialysis (HD). The geometric mean ceftaroline  $AUC_{0-\infty}$  following the post-HD infusion was  
450 167% higher compared to healthy subjects with normal renal function ( $CrCl > 80$  mL/min,  $n=6$ ). The mean  
451 recovery of ceftaroline in the dialysate following a 4-hour HD session was 76.5 mg, or 21.6% of the  
452 administered dose. Dosage adjustment is recommended in patients with ESRD (defined as  $CrCl < 15$   
453 mL/min), including patients on HD [*see Dosage and Administration (2.2)*].

454

### 455 **Hepatic Impairment**

456

457 The pharmacokinetics of ceftaroline in patients with hepatic impairment have not been established. As  
458 ceftaroline does not appear to undergo significant hepatic metabolism, the systemic clearance of ceftaroline  
459 is not expected to be significantly affected by hepatic impairment.

460

### 461 **Geriatric Patients**

462

463 Following administration of a single 600 mg IV dose of Teflaro to healthy elderly subjects ( $\geq 65$  years of  
464 age,  $n=16$ ), the geometric mean  $AUC_{0-\infty}$  of ceftaroline was ~33% higher compared to healthy young adult  
465 subjects (18-45 years of age,  $n=16$ ). The difference in  $AUC_{0-\infty}$  was mainly attributable to age-related  
466 changes in renal function. Dosage adjustment for Teflaro in elderly patients should be based on renal  
467 function [*see Dosage and Administration (2.2)*].

468

### 469 **Pediatric Patients**

470

471 The pharmacokinetics of ceftaroline were evaluated in adolescent patients (ages 12 to 17,  $n=7$ ) with normal  
472 renal function following administration of a single 8 mg/kg IV dose of Teflaro (or 600 mg for subjects  
473 weighing  $> 75$  kg). The mean plasma clearance and terminal phase volume of distribution for ceftaroline in  
474 adolescent subjects were similar to healthy adults ( $n=6$ ) in a separate study following administration of a  
475 single 600 mg IV dose. However, the mean  $C_{max}$  and  $AUC_{0-\infty}$  for ceftaroline in adolescent subjects who  
476 received a single 8 mg/kg dose were 10% and 23% less than in healthy adult subjects who received a single  
477 600 mg IV dose.

478

## 479 **Gender**

480

481 Following administration of a single 600 mg IV dose of Teflaro to healthy elderly males (n=10) and females  
482 (n=6) and healthy young adult males (n=6) and females (n=10), the mean  $C_{max}$  and  $AUC_{0-\infty}$  for ceftaroline  
483 were similar between males and females, although there was a trend for higher  $C_{max}$  (17%) and  $AUC_{0-\infty}$  (6-  
484 15%) in female subjects. Population pharmacokinetic analysis did not identify any significant differences in  
485 ceftaroline  $AUC_{0-\tau}$  based on gender in Phase 2/3 patients with ABSSSI or CABP. No dose adjustment is  
486 recommended based on gender.

487

## 488 **Race**

489

490 A population pharmacokinetic analysis was performed to evaluate the impact of race on the  
491 pharmacokinetics of ceftaroline using data from Phase 2/3 ABSSSI and CABP trials. No significant  
492 differences in ceftaroline  $AUC_{0-\tau}$  was observed across White (n=35), Hispanic (n=34), and Black (n=17)  
493 race groups for ABSSSI patients. Patients enrolled in CABP trials were predominantly categorized as White  
494 (n=115); thus there were too few patients of other races to draw any conclusions. No dosage adjustment is  
495 recommended based on race.

496

## 497 **Drug Interactions**

498

499 *In vitro* studies in human liver microsomes indicate that ceftaroline does not inhibit the major cytochrome  
500 P450 isoenzymes CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6,  
501 CYP2E1 and CYP3A4. *In vitro* studies in human hepatocytes also demonstrate that ceftaroline and its  
502 inactive open-ring metabolite are not inducers of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or  
503 CYP3A4/5. Therefore Teflaro is not expected to inhibit or induce the clearance of drugs that are  
504 metabolized by these metabolic pathways in a clinically relevant manner.

505

506 Population pharmacokinetic analysis did not identify any clinically relevant differences in ceftaroline  
507 exposure ( $C_{max}$  and  $AUC_{0-\tau}$ ) in Phase 2/3 patients with ABSSSI or CABP who were taking concomitant  
508 medications that are known inhibitors, inducers, or substrates of the cytochrome P450 system; anionic or  
509 cationic drugs known to undergo active renal secretion; and vasodilator or vasoconstrictor drugs that may  
510 alter renal blood flow.

511

## 512 **12.4 Microbiology**

513

### 514 **Mode of Action**

515

516 Ceftaroline is a cephalosporin with *in vitro* activity against Gram-positive and -negative bacteria. The  
517 bactericidal action of ceftaroline is mediated through binding to essential penicillin-binding proteins (PBPs).  
518 Ceftaroline is bactericidal against *S. aureus* due to its affinity for PBP2a and against *Streptococcus*  
519 *pneumoniae* due to its affinity for PBP2x.

520

### 521 **Mechanisms of Resistance**

522

523 Ceftaroline is not active against Gram-negative bacteria producing extended spectrum beta-lactamases  
524 (ESBLs) from the TEM, SHV or CTX-M families, serine carbapenemases (such as KPC), class B metallo-  
525 beta-lactamases, or class C (AmpC cephalosporinases).

526

527 **Cross-Resistance**

528

529 Although cross-resistance may occur, some isolates resistant to other cephalosporins may be susceptible to  
530 ceftaroline.

531

532 **Interaction with Other Antimicrobials**

533

534 *In vitro* studies have not demonstrated any antagonism between ceftaroline or other commonly used  
535 antibacterial agents (e.g., vancomycin, linezolid, daptomycin, levofloxacin, azithromycin, amikacin,  
536 aztreonam, tigecycline, and meropenem).

537

538 Ceftaroline has been shown to be active against most of the following bacteria, both *in vitro* and in clinical  
539 infections [see *Indications and Usage (1)*].

540

541 **Skin Infections**

542

543 Gram-positive bacteria

544 *Staphylococcus aureus* (including methicillin-susceptible and -resistant isolates)

545 *Streptococcus pyogenes*

546 *Streptococcus agalactiae*

547

548 Gram-negative bacteria

549 *Escherichia coli*

550 *Klebsiella pneumoniae*

551 *Klebsiella oxytoca*

552

553 **Community-Acquired Bacterial Pneumonia (CABP)**

554

555 Gram-positive bacteria

556 *Streptococcus pneumoniae*

557 *Staphylococcus aureus* (methicillin-susceptible isolates only)

558

559 Gram-negative bacteria

560 *Haemophilus influenzae*

561 *Klebsiella pneumoniae*

562 *Klebsiella oxytoca*

563 *Escherichia coli*

564

565 The following *in vitro* data are available, but their clinical significance is unknown. Ceftaroline exhibits *in*  
566 *vitro* MICs of 1 mcg/mL or less against most ( $\geq 90\%$ ) isolates of the following bacteria; however, the safety  
567 and effectiveness of Teflaro in treating clinical infections due to these bacteria have not been established in  
568 adequate and well-controlled clinical trials.

569

570 Gram-positive bacteria

571

572 *Streptococcus dysgalactiae*

573

574 Gram-negative bacteria  
 575  
 576 *Citrobacter koseri*  
 577 *Citrobacter freundii*  
 578 *Enterobacter cloacae*  
 579 *Enterobacter aerogenes*  
 580 *Moraxella catarrhalis*  
 581 *Morganella morganii*  
 582 *Proteus mirabilis*  
 583 *Haemophilus parainfluenzae*

584

585 **Susceptibility Test Methods**

586

587 When available, the clinical microbiology laboratory should provide the results of *in vitro* susceptibility test  
 588 results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports  
 589 that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports  
 590 should aid the physician in selecting an antibacterial drug product for treatment.

591

592 **Dilution Techniques**

593

594 Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These  
 595 MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be  
 596 determined using a standardized test method<sup>1,3</sup>, (broth, and/or agar). Broth dilution MICs need to be read  
 597 within 18 hours due to degradation of ceftaroline activity by 24 hours. The MIC values should be interpreted  
 598 according to the criteria in Table 6.

599

600 **Diffusion Techniques**

601

602 Quantitative methods that require measurement of zone diameters can also provide reproducible estimates  
 603 of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the  
 604 susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a  
 605 standardized method. This procedure uses paper disks impregnated with 30 mcg of ceftaroline to test the  
 606 susceptibility of bacteria to ceftaroline. The disk diffusion interpretive criteria are provided in Table 6.

607

608

**Table 6: Susceptibility Interpretive Criteria for Ceftaroline**

Pathogen and Isolate Source	Minimum Inhibitory Concentrations (mcg/mL)			Disk Diffusion Zone Diameter (mm)		
	S	I	R	S	I	R
<i>Staphylococcus aureus</i> (includes methicillin-resistant isolates - skin isolates only) -See NOTE below	≤ 1	2	≥ 4	≥ 24	21-23	≤ 20
<i>Streptococcus agalactiae</i> <sup>a</sup> (skin isolates only)	≤ 0.5	—	—	≥ 26	—	—
<i>Streptococcus pyogenes</i> <sup>a</sup> (skin isolates only)	≤ 0.5	—	—	≥ 26	—	—

<i>Streptococcus pneumoniae</i> <sup>a</sup> (CABP isolates only)	≤ 0.5	—	—	≥ 26	—	—
<i>Haemophilus influenzae</i> <sup>a</sup> (CABP isolates only)	≤ 0.5	—	—	≥ 30	—	—
<i>Enterobacteriaceae</i> <sup>b</sup> (CABP and skin isolates)	≤ 0.5	1	≥ 2	≥ 23	20-22	≤ 19

S = susceptible, I = intermediate, R = resistant

**NOTE:** Clinical efficacy of Teflaro to treat lower respiratory infections such as community-acquired bacterial pneumonia due to MRSA has not been studied in adequate and well controlled trials (See “Clinical Trials” section 14)

<sup>a</sup> The current absence of resistant isolates precludes defining any results other than “Susceptible.” Isolates yielding MIC results other than “Susceptible” should be submitted to a reference laboratory for further testing.

<sup>b</sup> Clinical efficacy was shown for the following *Enterobacteriaceae*: *Escherichia coli*, *Klebsiella pneumoniae*, and *Klebsiella oxytoca*.

A report of “Susceptible” indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentration at the infection site necessary to inhibit growth of the pathogen. A report of “Intermediate” indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.

### Quality Control

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test.<sup>1,2,3</sup> Standard ceftaroline powder should provide the following range of MIC values provided in Table 7. For the diffusion technique using the 30-mcg ceftaroline disk the criteria provided in Table 7 should be achieved.

**Table 7: Acceptable Quality Control Ranges for Susceptibility Testing**

Quality Control Organism	Minimum Inhibitory Concentrations (mcg/mL)	Disk Diffusion (zone diameters in mm)
<i>Staphylococcus aureus</i> ATCC 25923	Not Applicable	26-35
<i>Staphylococcus aureus</i> ATCC 29213	0.12-0.5	Not Applicable
<i>Escherichia coli</i> ATCC 25922	0.03-0.12	26-34
<i>Haemophilus influenzae</i> ATCC 49247	0.03-0.12	29-39
<i>Streptococcus pneumoniae</i> ATCC 49619	0.008-0.03	31-41

ATCC = American Type Culture Collection

638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685

### 13. NONCLINICAL TOXICOLOGY

#### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term carcinogenicity studies have not been conducted with ceftaroline. Ceftaroline fosamil did not show evidence of mutagenic activity in *in vitro* tests that included a bacterial reverse mutation assay and the mouse lymphoma assay. Ceftaroline was not mutagenic in an *in vitro* mammalian cell assay. *In vivo*, ceftaroline fosamil did not induce unscheduled DNA synthesis in rat hepatocytes and did not induce the formation of micronucleated erythrocytes in mouse or rat bone marrow. Both ceftaroline fosamil and ceftaroline were clastogenic in the absence of metabolic activation in an *in vitro* chromosomal aberration assays, but not in the presence of metabolic activation.

IV injection of ceftaroline fosamil had no adverse effects on fertility of male and female rats given up to 450 mg/kg. This is approximately 4-fold higher than the maximum recommended human dose based on body surface area.

### 14. CLINICAL TRIALS

#### 14.1 Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

A total of 1396 adults with clinically documented complicated skin and skin structure infection were enrolled in two identical randomized, multi-center, multinational, double-blind, non-inferiority trials (Trials 1 and 2) comparing Teflaro (600 mg administered IV over 1 hour every 12 hours) to vancomycin plus aztreonam (1 g vancomycin administered IV over 1 hour followed by 1 g aztreonam administered IV over 1 hour every 12 hours). Treatment duration was 5 to 14 days. A switch to oral therapy was not allowed. The Modified Intent-to-Treat (MITT) population included all patients who received any amount of study drug according to their randomized treatment group. The CE population included patients in the MITT population who demonstrated sufficient adherence to the protocol.

To evaluate the treatment effect of ceftaroline, an analysis was conducted in 797 patients with ABSSSI (such as deep/extensive cellulitis or a wound infection [surgical or traumatic]) for whom the treatment effect of antibacterials may be supported by historical evidence. This analysis evaluated responder rates based on achieving both cessation of lesion spread and absence of fever on Trial Day 3 in the following subgroup of patients:

Patients with lesion size  $\geq 75$  cm<sup>2</sup> and having one of the following infection types:

- Major abscess with  $\geq 5$  cm of surrounding erythema
- Wound infection
- Deep/extensive cellulitis

686 The results of this analysis are shown in Table 8.

687  
688

**Table 8: Clinical Responders at Study Day 3 from Two Phase 3 ABSSSI Trials**

	<b>Teflaro n/N (%)</b>	<b>Vancomycin/ Aztreonam n/N (%)</b>	<b>Treatment Difference (2-sided 95% CI)</b>
<b>ABSSSI Trial 1</b>	148/200 (74.0)	135/209 (64.6)	9.4 (0.4, 18.2)
<b>ABSSSI Trial 2</b>	148/200 (74.0)	128/188 (68.1)	5.9 (-3.1, 14.9)

689

690 The protocol-specified analyses included clinical cure rates at the Test of Cure (TOC) (visit 8 to 15 days  
691 after the end of therapy) in the co-primary CE and MITT populations (Table 9) and clinical cure rates at  
692 TOC by pathogen in the Microbiologically Evaluable (ME) population (Table 10). However, there are  
693 insufficient historical data to establish the magnitude of drug effect for antibacterial drugs compared with  
694 placebo at a TOC time point. Therefore, comparisons of Teflaro to vancomycin plus aztreonam based on  
695 clinical response rates at TOC can not be utilized to establish non-inferiority.

696  
697  
698

**Table 9: Clinical Cure Rates at TOC from Two Phase 3 ABSSSI Trials**

	<b>Teflaro n/N (%)</b>	<b>Vancomycin/ Aztreonam n/N (%)</b>	<b>Treatment Difference (2-sided 95% CI)</b>
<b>Trial 1</b>			
<b>CE</b>	288/316 (91.1)	280/300 (93.3)	-2.2 (-6.6, 2.1)
<b>MITT</b>	304/351 (86.6)	297/347 (85.6)	1.0 (-4.2, 6.2)
<b>Trial 2</b>			
<b>CE</b>	271/294 (92.2)	269/292 (92.1)	0.1 (-4.4, 4.5)
<b>MITT</b>	291/342 (85.1)	289/338 (85.5)	-0.4 (-5.8, 5.0)

699  
700  
701  
702

**Table 10: Clinical Cure Rates at TOC by Pathogen  
from Two Integrated Phase 3 ABSSSI Trials**

	<b>Teflaro n/N (%)</b>	<b>Vancomycin/Aztreonam n/N (%)</b>
<b>Gram-positive:</b>		
MSSA (methicillin-susceptible)	212/228 (93.0%)	225/238 (94.5%)
MRSA (methicillin-resistant)	142/152 (93.4%)	115/122 (94.3%)
<i>Streptococcus pyogenes</i>	56/56 (100%)	56/58 (96.6%)
<i>Streptococcus agalactiae</i>	21/22 (95.5%)	18/18 (100%)
<b>Gram-negative:</b>		
<i>Escherichia coli</i>	20/21 (95.2%)	19/21 (90.5%)
<i>Klebsiella pneumoniae</i>	17/18 (94.4%)	13/14 (92.9%)
<i>Klebsiella oxytoca</i>	10/12 (83.3%)	6/6 (100%)

703  
704  
705

## 14.2 Community-Acquired Bacterial Pneumonia (CABP)

706 A total of 1231 adults with a diagnosis of CABP were enrolled in two randomized, multi-center,  
707 multinational, double-blind, non-inferiority trials (Trials 1 and 2) comparing Teflaro (600 mg administered  
708 IV over 1 hour every 12 hours) with ceftriaxone (1 g ceftriaxone administered IV over 30 minutes every 24  
709 hours). In both treatment groups of CABP Trial 1, two doses of oral clarithromycin (500 mg every 12  
710 hours), were administered as adjunctive therapy starting on Study Day 1. No adjunctive macrolide therapy  
711 was used in CABP Trial 2. Patients with known or suspected MRSA were excluded from both trials.

712 Patients with new or progressive pulmonary infiltrate(s) on chest radiography and signs and symptoms  
 713 consistent with CABP with the need for hospitalization and IV therapy were enrolled in the trials. Treatment  
 714 duration was 5 to 7 days. A switch to oral therapy was not allowed. Among all subjects who received any  
 715 amount of study drug in the two CABP trials, the 30-day all-cause mortality rates were 11/609 (1.8%) for  
 716 the Teflaro group vs. 12/610 (2.0%) for the ceftriaxone group, and the difference in mortality rates was not  
 717 statistically significant.

718

719 To evaluate the treatment effect of ceftaroline, an analysis was conducted in CABP patients for whom the  
 720 treatment effect of antibacterials may be supported by historical evidence. The analysis endpoint required  
 721 subjects to meet sign and symptom criteria at Day 4 of therapy: a responder had to both (a) be in stable  
 722 condition according to consensus treatment guidelines of the Infectious Diseases Society of America and  
 723 American Thoracic Society, based on temperature, heart rate, respiratory rate, blood pressure, oxygen  
 724 saturation, and mental status;<sup>4</sup> (b) show improvement from baseline on at least one symptom of cough,  
 725 dyspnea, pleuritic chest pain, or sputum production, while not worsening on any of these four symptoms.  
 726 The analysis used a microbiological intent-to-treat population (mITT population) containing only subjects  
 727 with a confirmed bacterial pathogen at baseline. Results for this analysis are presented in Table 11.  
 728

729

**Table 11: Response Rates at Study Day 4 (72-96 hours) from Two Phase 3 CABP Trials**

	<b>Teflaro n/N (%)</b>	<b>Ceftriaxone n/N (%)</b>	<b>Treatment Difference (2-sided 95% CI)</b>
<b>CABP Trial 1</b>	48/69 (69.6%)	42/72 (58.3%)	11.2 (-4.6,26.5)
<b>CABP Trial 2</b>	58/84 (69.0%)	51/83 (61.4%)	7.6 (-6.8,21.8)

730

731 The protocol-specified analyses included clinical cure rates at the TOC (8 to 15 days after the end of  
 732 therapy) in the co-primary Modified Intent-to-Treat Efficacy (MITTE) and CE populations (Table 12) and  
 733 clinical cure rates at TOC by pathogen in the Microbiologically Evaluable (ME) population (Table 13).  
 734 However, there are insufficient historical data to establish the magnitude of drug effect for antibacterials  
 735 drugs compared with placebo at a TOC time point. Therefore, comparisons of Teflaro to ceftriaxone based  
 736 on clinical response rates at TOC cannot be utilized to establish non-inferiority. Neither trial established that  
 737 Teflaro was statistically superior to ceftriaxone in terms of clinical response rates. The MITTE population  
 738 included all patients who received any amount of study drug according to their randomized treatment group  
 739 and were in PORT (Pneumonia Outcomes Research Team) Risk Class III or IV. The CE population  
 740 included patients in the MITTE population who demonstrated sufficient adherence to the protocol.  
 741

741

742

**Table 12: Clinical Cure Rates at TOC from Two Phase 3 CABP Trials**

	<b>Teflaro n/N (%)</b>	<b>Ceftriaxone n/N (%)</b>	<b>Treatment Difference (2-sided 95% CI)</b>
<b>CABP Trial 1</b>			
<b>CE</b>	194/224 (86.6%)	183/234 (78.2%)	8.4 (1.4, 15.4)
<b>MITTE</b>	244/291 (83.8%)	233/300 (77.7%)	6.2 (-0.2, 12.6)
<b>CABP Trial 2</b>			
<b>CE</b>	191/232 (82.3%)	165/214 (77.1%)	5.2 (-2.2, 12.8)
<b>MITTE</b>	231/284 (81.3%)	203/269 (75.5%)	5.9 (-1.0, 12.8)

743  
744

**Table 13: Clinical Cure Rates at TOC  
by Pathogen from Two Integrated Phase 3 CABP Trials**

	<b>Teflaro n/N (%)</b>	<b>Ceftriaxone n/N (%)</b>
<b>Gram-positive:</b>		
<i>Streptococcus pneumoniae</i>	54/63 (85.7%)	41/59 (69.5%)
<i>Staphylococcus aureus</i> (methicillin-susceptible isolates only)	18/25 (72.0%)	14/25 (56.0%)
<b>Gram-negative:</b>		
<i>Haemophilus influenzae</i>	15/18 (83.3%)	17/20 (85.0%)
<i>Klebsiella pneumoniae</i>	12/12 (100%)	10/12 (83.3%)
<i>Klebsiella oxytoca</i>	5/6 (83.3%)	7/8 (87.5%)
<i>Escherichia coli</i>	10/12 (83.3%)	9/12 (75.0%)

745 **15. REFERENCES**

- 746
- 747 1. Clinical and Laboratory Standards Institute (CLSI). *Methods for Dilution Antimicrobial*
- 748 *Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Ninth Edition*. CLSI
- 749 document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500,
- 750 Wayne, Pennsylvania 19087, USA, 2012.
- 751
- 752 2. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Disk*
- 753 *Diffusion Susceptibility Tests; Approved Standard – Eleventh Edition* CLSI document M02-A11,
- 754 Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne,
- 755 Pennsylvania 19087, USA, 2012.
- 756
- 757 3. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial*
- 758 *Susceptibility Testing; Twenty-third Informational Supplement*, CLSI document M100-S23. CLSI
- 759 document M100-S23, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite
- 760 2500, Wayne, Pennsylvania 19087, USA, 2013.
- 761
- 762 4. Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., Dowell,
- 763 S.F., File, T.M., Musher, D.M., Niederman, M.S., Torres, A., Whitney, C.G. Infectious Diseases
- 764 Society of America/American Thoracic Society consensus guidelines on the management of
- 765 community-acquired pneumonia in adults. *Clinical Infectious Disease*. 2007; 44:S27-72.
- 766
- 767

768 **16. HOW SUPPLIED/STORAGE AND HANDLING**

769 Teflaro (ceftaroline fosamil) for injection is supplied in single-use, clear glass vials containing:

- 770
- 771 • 600 mg - individual vial (NDC 0456-0600-01) and carton containing 10 vials (NDC 0456-0600-10)
  - 772 • 400 mg - individual vial (NDC 0456-0400-01) and carton containing 10 vials (NDC 0456-0400-10)
- 773
- 774

775 Teflaro vials should be stored refrigerated at 2 to 8° C (36 to 46° F). Unrefrigerated, unreconstituted Teflaro

776 can be stored at temperatures not exceeding 25°C (77°F) for no more than 7 days.

777

778

779 **17. PATIENT COUNSELING INFORMATION**

780

781 • Patients should be advised that allergic reactions, including serious allergic reactions, could occur and  
782 that serious reactions require immediate treatment. They should inform their healthcare provider about  
783 any previous hypersensitivity reactions to Teflaro, other beta-lactams (including cephalosporins) or  
784 other allergens.

785

786 • Patients should be counseled that antibacterial drugs including Teflaro should be used to treat only  
787 bacterial infections. They do not treat viral infections (e.g., the common cold). When Teflaro is  
788 prescribed to treat a bacterial infection, patients should be told that although it is common to feel better  
789 early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not  
790 completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and  
791 (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Teflaro or  
792 other antibacterial drugs in the future.

793

794 • Patients should be advised that diarrhea is a common problem caused by antibacterial drugs and usually  
795 resolves when the drug is discontinued. Sometimes, frequent watery or bloody diarrhea may occur and  
796 may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops,  
797 patients should contact their healthcare provider.

798

799 • Keep out of reach of children

800

801 Teflaro<sup>®</sup> (ceftaroline fosamil) for injection

802

803

804

805 **Distributed by:**

806

807 Forest Pharmaceuticals, Inc.

808 Subsidiary of Forest Laboratories, Inc.

809 St. Louis, MO 63045, USA

810

811 **Manufactured by:**

812

813 Facta Farmaceutici S.p.A.

814 Nucleo Industriale S. Atto–S. Nicolò a Tordino

815 64020 Teramo, Italy

816

817 Teflaro is a registered trademark of Forest Laboratories, Inc.

818 Baxter<sup>®</sup> is a registered trademark and Mini-Bag Plus<sup>™</sup> is a trademark of Baxter International Inc.

819

820 **IF95USCFRXX**

821

822 ©2010-2012 Forest Laboratories, Inc. All rights reserved.

823